Abstract
Introduction

Bone marrow harbours cells of haematopoietic and nonhaematopoietic lineages and their precursors, known as stem/ progenitor cells. The non-haematopoietic stem/progenitor cell compartment contains mesenchymal stem cells (MSCs), which are involved in remodelling of the mesenchymal tissues throughout adult life. These multi-potent cells are easily isolated from bone marrow and are capable of expansion and differentiation into mesodermal lineage cells including osteoblasts, chondrocytes and adipocytes, under appropriate conditions, in culture
. This led to the evaluation of their potential for treating diseases and the birth of MSC-based therapy.
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promise [3] [4] [5] [6] . Numerous 
Mesenchymal stem cells and its characteristics
MSCs were first identified about 30 years ago by Friedenstein and colleagues as an adherent fibroblast-like population in the bone marrow capable of differentiating into bone [17] . Since then MSCs have been isolated from human bone marrow based on their ability to adhere to tissue culture plastic [1] . Although occurring at a very low frequency of 1 in 10,000 to 100,000 bone marrow mononuclear cells, these cells are capable of proliferating in vitro without significant loss of differentiation potential during early passages [1, 2, 18] .
Originally isolated from the bone marrow, similar populations have also been isolated from peripheral blood [19] , periosteum [20] , umbilical cord blood [21] (Fig. 2) . [95] , but whether human MSCs also exhibit similar effect remains to be determined. Another contributing factor is low cell survival rate after transplantation [96, 97] . Thus, preconditioning of MSCs prior to transplant by culturing in presence of SDF-1 [98] or under hypoxic conditions [99, 100] [193] with [149] . No side effects were observed after HLAidentical or mismatched MSC infusions [148] , and the response rate was not related to donor HLA match [149] . On (Fig. 2) .
MSC transplantation
Genetically modified MSC-based therapy
Integrating the strengths of genetic engineering and stem cell biology holds tremendous potential for designing treatments for critical injuries and diseases by inducing differentiation into a specific
significantly greater amount of bone within the pore space of implants loaded with MSCs than cell-free implants [137]. This study highlights the immunomodulatory functions of MSCs, which prevented any immune rejection against transplanted cells as well as ability of MSCs to differentiate into osteoblasts and repair the bone defect. Generation of complex three-dimensional tissue grafts is confronted by problem of supply of nutrients to the cells deep inside the graft. Vascularization of the graft is essential for the survival of cells and sustenance of the implant. Although host blood vessels invade the implant in response to signals secreted by implanted cells because of oxygen deficiency, it occurs at very slow pace and would require weeks to vasculate an implant of few millimetres [138], leading to death of cells inside the implant. Endothelial precursor cells (EPCs) and pro-angiogenic factors such as VEGF have been used for the generation of vascularized grafts [139]. They can be used either by mixing EPCs and MSCs or by transfecting MSCs with VEGF gene to promote angiogenesis in vivo upon transplant [140]. Human MSCs coupled with human umbilical vein endothelial cells were used to generate vascularized bone in vitro, but no perfusion was observed upon implantation [141]. No vascularization strategy is available at present that can support large constructs after implantation. Current approaches such as in vivo prevascularization, in vitro prevascularization, use of scaffold and angiogenic factor delivery (reviewed in [142]) are only likely to increase the chances of vascularization of the implant, because each has certain limitations. In vivo evaluation of proper integration of the implant at the injury site and its long-term persistence using imaging techniques are required to ensure safety and facilitate further improvements because neovascularization mediated by VEGF alone may produce non-functional vessel with defective cellular differentiation [143].
Clinical studies
Encouraging results of tissue repair and immunomodulation in animal studies have led to limited clinical studies with MSCs for some debilitating disorders (Table 5). Metachromatic leucodystrophy (MLD) and Hurler syndrome are autosomal recessive disorders due to deficiency of enzymes arylsulfatase A and ␣-Liduronidase, respectively. These patients develop neurological and musculoskeletal defects that limit their survival [56]. HSC transplantation significantly improves survival of patients but abnormalities still persist. Koc and colleagues postulated that infusion of MSCs might correct the defects because they are capable of differentiating into mesenchymal and neuronal cells [56]. Patients undergone HSC transplant were infused with MSCs from the same donor and demonstrated no infusion-related toxicity. Donor derived-MSCs constituted only 0.4 and 2% of MSCs from 2 of 11 patients enrolled in the study. Although MLD patients showed significant improvement in nerve conduction velocity, no change in overall health of the patients was apparent. The study demonstrated the safety of allogeneic MSC transplantation and highlights the low engraftment efficiency of culture-expanded MSCs, which could be either because of poor survival following transplant, proliferative defect or low homing ability of cultured MSCs [56]. However more studies are required to investigate any role of MSC in the treatment of MLD and Hurler syndrome. MI caused by an imbalance between the oxygen supply and the demand of the myocardium results in the development of myocardial necrosis. Thus, the restoration of functional cardiomyocytes in the infarcted myocardium is the only solution. Because MSCs have been demonstrated to differentiate into cardiomyocytes in vitro as well as in animal model of MI [144, 145], Chen and colleagues planned a randomized study to investigate
Because 
